Related Experiment Video

Updated: Sep 17, 2025

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations
11:52

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Published on: August 4, 2016

10.5K

Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study

Pam K Mangat1, M Kelsey Kirkwood2, Dominique C Hinshaw2

  • 1American Society of Clinical Oncology, Alexandria, VA, USA. TAPURPublications@asco.org.

NPJ Precision Oncology
|July 3, 2025
PubMed

Insights

The Targeted Agent and Profiling Utilization (TAPUR) study found that specific gene alterations, like PDGRFA and JAK2, are more common in certain ethnic groups. This highlights the need for diverse patient populations in clinical trials for tailored cancer treatments.

Area of Science:

  • Oncology
  • Genomics
  • Clinical Trials

Background:

  • The Targeted Agent and Profiling Utilization (TAPUR) Study (NCT02693535) is a Phase II basket trial.
  • It evaluates targeted therapies in advanced cancers with known drug targets.
  • Understanding genomic alterations across diverse populations is crucial for effective treatment.

Purpose of the Study:

  • To analyze the prevalence of targetable gene alterations in a diverse patient cohort.
  • To investigate the association of these alterations with demographic factors.
  • To inform the development of personalized cancer treatment strategies.

Main Methods:

  • Analysis of 978 gene alterations and biomarkers in 3448 registrants.
  • Assessment across various demographic factors including sex, age, race, ethnicity, BMI, smoking status, performance status, and cancer type.
  • Utilized data from the TAPUR Study (ClinicalTrials.gov NCT02693535).

Main Results:

  • Identified higher prevalence of PDGRFA in Hispanic versus non-Hispanic registrants.
  • Observed higher prevalence of JAK2 in Asian versus White registrants.
  • Demonstrated demographic variations in the occurrence of targetable genomic alterations.

Conclusions:

  • Recruiting diverse patient populations to clinical trials is essential.
  • Genomic target prevalence varies significantly across different demographic groups.
  • Treatment strategies may benefit from integrating patient demographics with tumor characteristics.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.0K